NCT02536755View on ClinicalTrials.gov

Phase 3b Study to Evaluate Skeletal Response to Eliglustat in Adult Patients Who Completed Phase 2 or Phase 3 Studies

PHASE3CompletedINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

October 27, 2015

Primary Completion Date

June 24, 2021

Study Completion Date

June 24, 2021

Conditions

Gaucher Disease

Interventions

DRUG

Eliglustat, GZ385660

"Pharmaceutical form: capsule~Route of administration: oral"

Trial Locations (4)

1007

Investigational Site Number 788001, Tunis

125167

Investigational Site Number 643001, Moscow

197341

Investigational Site Number 643002, Saint Petersburg

H3T 1E2

Investigational Site Number 124002, Montreal

All Listed Sponsors

lead

Genzyme, a Sanofi Company

INDUSTRY

NCT02536755 - Phase 3b Study to Evaluate Skeletal Response to Eliglustat in Adult Patients Who Completed Phase 2 or Phase 3 Studies | Biotech Hunter | Biotech Hunter